Back to search results
NCT06986447

Assessment of Non-Invasive Testing in Major Liver-Related Outcomes

Enrolling by Invitation
Not specifiedAges 18–80Observational
HRI-MAIL-NIT
~1,689 participants
Updated 2026-03-27 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Occurrence of major adverse liver outcomes (MALO)
Measured over 2 years

Conditions

Metabolic Dysfunction-Associated Steatotic Liver Disease
MASLD
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
MetALD

Explore related trials

Metabolic Dysfunction-Associated Steatotic Liver Disease and Alcohol-Related Liver DiseaseNonalcoholic Steatohepatitis

NCT06986447

Where you'd take part

This study runs at 8 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Arizona Liver Health

    Chandler, Arizonano site contact published

  • Arizona Liver Health

    Peoria, Arizonano site contact published

  • Arizona Liver Health

    Tucson, Arizonano site contact published

  • CRIOH

    Westlake, Ohiono site contact published

  • Houston Research Institute - Dairy Ashford

    Houston, Texasno site contact published

  • Houston Research Institute - Medical Center

    Houston, Texasno site contact published

  • Houston Research Institute - Pasadena

    Pasadena, Texasno site contact published

  • Houston Research Institute - Sugar Land

    Sugar Land, Texasno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Mazen Noureddin, MD, MHSc · PRINCIPAL_INVESTIGATOR · Houston Research Institute

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Occurrence of major adverse liver outcomes (MALO)2 years

    Variceal bleeding, hepatic encephalopathy, ascites, progression from MELD 13 to 15, liver transplant, death attributable to liver disease, progression to large varices